company background image
ZLAB logo

Zai Lab NasdaqGM:ZLAB Stock Report

Last Price

US$16.02

Market Cap

US$1.6b

7D

-7.1%

1Y

-52.5%

Updated

28 Mar, 2024

Data

Company Financials +

ZLAB Stock Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.

ZLAB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Zai Lab Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zai Lab
Historical stock prices
Current Share PriceUS$16.02
52 Week HighUS$40.42
52 Week LowUS$15.69
Beta1.13
1 Month Change-28.77%
3 Month Change-41.38%
1 Year Change-52.51%
3 Year Change-87.77%
5 Year Change-48.60%
Change since IPO-11.00%

Recent News & Updates

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Mar 29
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Recent updates

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Mar 29
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Jan 18
Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24
Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Jun 02
We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?

Feb 16
Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?

Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans

Jan 20
Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Sep 19
We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M

Aug 09

China accepts Zai Lab's biologics license application for neuromuscular disorder drug

Jul 13

Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth

Jun 03
Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth

As Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?

May 18

Zai Lab Revenue Triples As It Struggles To Break Cycle Of Mounting Losses

Mar 08

Bearish: Analysts Just Cut Their Zai Lab Limited (NASDAQ:ZLAB) Revenue and EPS estimates

Mar 06
Bearish: Analysts Just Cut Their Zai Lab Limited (NASDAQ:ZLAB) Revenue and EPS estimates

Shareholder Returns

ZLABUS BiotechsUS Market
7D-7.1%0.9%0.2%
1Y-52.5%11.0%28.1%

Return vs Industry: ZLAB underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: ZLAB underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is ZLAB's price volatile compared to industry and market?
ZLAB volatility
ZLAB Average Weekly Movement8.0%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ZLAB's share price has been volatile over the past 3 months.

Volatility Over Time: ZLAB's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20132,175Samantha Duhttps://www.zailaboratory.com

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.

Zai Lab Limited Fundamentals Summary

How do Zai Lab's earnings and revenue compare to its market cap?
ZLAB fundamental statistics
Market capUS$1.60b
Earnings (TTM)-US$334.62m
Revenue (TTM)US$266.72m

5.9x

P/S Ratio

-4.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZLAB income statement (TTM)
RevenueUS$266.72m
Cost of RevenueUS$361.68m
Gross Profit-US$94.96m
Other ExpensesUS$239.66m
Earnings-US$334.62m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.39
Gross Margin-35.60%
Net Profit Margin-125.46%
Debt/Equity Ratio0%

How did ZLAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.